Ethinylestradiol is a synthetic estrogen commonly used in hormonal contraceptives and hormone replacement therapy. It is characterized by its potent estrogenic activity, which is significantly stronger than that of natural estradiol. Ethinylestradiol is a white to off-white crystalline powder that is poorly soluble in water but soluble in organic solvents like ethanol and acetone. Its molecular formula is C20H24O2, and it has a molecular weight of approximately 296.4 g/mol. The compound features an ethynyl group at the C17 position, which enhances its oral bioavailability and metabolic stability compared to natural estrogens. Ethinylestradiol acts by binding to estrogen receptors, influencing gene expression and various physiological processes, including the regulation of the menstrual cycle and reproductive system. Due to its effectiveness, it is widely incorporated into various contraceptive formulations, often in combination with progestins. However, its use is associated with potential side effects, including an increased risk of thromboembolic events, necessitating careful consideration in prescribing practices.

Ethinylestradiol

100019-04-3: Ethinylestradiol is a synthetic estrogen commonly used in hormonal contraceptives and hormone replacement therapy. It is characterized by its potent estrogenic activity, which is significantly stronger than that of natural estradiol. Ethinylestradiol is a white to off-white crystalline powder that is poorly soluble in water but soluble in organic solvents like ethanol and acetone. Its molecular formula is C20H24O2, and it has a molecular weight of approximately 296.4 g/mol. The compound features an ethynyl group at the C17 position, which enhances its oral bioavailability and metabolic stability compared to natural estrogens. Ethinylestradiol acts by binding to estrogen receptors, influencing gene expression and various physiological processes, including the regulation of the menstrual cycle and reproductive system. Due to its effectiveness, it is widely incorporated into various contraceptive formulations, often in combination with progestins. However, its use is associated with potential side effects, including an increased risk of thromboembolic events, necessitating careful consideration in prescribing practices.

CAS 100019-04-3

Ethinylestradiol

δ-8(9)-Ethinyl Estradiol

Ref: ST-EA-CP-E21019